GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chinook Therapeutics Inc (NAS:KDNY) » Definitions » Forward Rate of Return (Yacktman) %

Chinook Therapeutics (Chinook Therapeutics) Forward Rate of Return (Yacktman) % : 0.00% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Chinook Therapeutics Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Chinook Therapeutics's forward rate of return for was 0.00%.

The historical rank and industry rank for Chinook Therapeutics's Forward Rate of Return (Yacktman) % or its related term are showing as below:

KDNY's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.65
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Chinook Therapeutics Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Chinook Therapeutics's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chinook Therapeutics Forward Rate of Return (Yacktman) % Chart

Chinook Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Forward Rate of Return (Yacktman) %
- - - -

Chinook Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chinook Therapeutics's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Chinook Therapeutics's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chinook Therapeutics's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chinook Therapeutics's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Chinook Therapeutics's Forward Rate of Return (Yacktman) % falls into.



Chinook Therapeutics Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Chinook Therapeutics's Forward Rate of Return of Jun. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/38.42+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chinook Therapeutics  (NAS:KDNY) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Chinook Therapeutics Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Chinook Therapeutics's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chinook Therapeutics (Chinook Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
400 Fairview Avenue North, Suite 900, Seattle, WA, USA, 98109
Chinook Therapeutics Inc is a clinical-stage biotechnology company. The products of the company are focused on rare, severe chronic kidney disorders. The clinical program is atrasentan, a potent and selective endothelin A receptor antagonist and currently conducting the phase 3 ALIGN trial of atrasentan for IgA nephropathy (IgAN) and the phase 2 AFFINITY basket trial for proteinuric glomerular diseases. The second product candidate, BION-1301, is an anti-APRIL monoclonal antibody and the third product candidate is CHK-336, an oral small-molecule LDHA inhibitor for the treatment of primary and idiopathic hyperoxaluria. It is incorporated in Delaware and is headquartered in Seattle, Washington.
Executives
Andrew James King officer: Head of Renal Discovery C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
William Mariner Greenman director C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Eric Dobmeier director, officer: President, CEO C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Mahesh Krishnan director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Andrew Oxtoby officer: Chief Commercial Officer 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Tom Frohlich officer: Chief Business Officer C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Bjerkholt officer: Chief Financial Officer 132 PURDURE AVENUE, KENGSINGTON CA 94708
Dolca Thomas director C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Alan Glicklich officer: Chief Medical Officer C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Versant Voyageurs I, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

Chinook Therapeutics (Chinook Therapeutics) Headlines